Clinical Trial Update: A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation [Phase 3]

View source ↗

Summary

Phase 3 study assessing valganciclovir for CMV prophylaxis after renal transplantation has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections
• Renal Transplantation

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cytomegalovirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2020-03-11